Free Trial

Vor Biopharma (VOR) Competitors

Vor Biopharma logo
$2.98 +1.07 (+56.16%)
As of 03:48 PM Eastern

VOR vs. IMNM, SNDX, CMRX, CDMO, AVXL, SION, QURE, AVBP, CRON, and XERS

Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Immunome (IMNM), Syndax Pharmaceuticals (SNDX), Chimerix (CMRX), Avid Bioservices (CDMO), Anavex Life Sciences (AVXL), Sionna Therapeutics (SION), uniQure (QURE), ArriVent BioPharma (AVBP), Cronos Group (CRON), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.

Vor Biopharma vs. Its Competitors

Immunome (NASDAQ:IMNM) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Vor Biopharma has lower revenue, but higher earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immunome$9.04M84.70-$292.96M-$3.18-2.77
Vor BiopharmaN/AN/AN/A-$1.51-1.98

Immunome currently has a consensus price target of $23.33, indicating a potential upside of 165.15%. Vor Biopharma has a consensus price target of $5.63, indicating a potential upside of 88.71%. Given Immunome's stronger consensus rating and higher probable upside, analysts clearly believe Immunome is more favorable than Vor Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunome
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Vor Biopharma
0 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.60

Immunome has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500.

In the previous week, Vor Biopharma had 8 more articles in the media than Immunome. MarketBeat recorded 10 mentions for Vor Biopharma and 2 mentions for Immunome. Immunome's average media sentiment score of 0.70 beat Vor Biopharma's score of 0.26 indicating that Immunome is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immunome
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vor Biopharma
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Vor Biopharma has a net margin of 0.00% compared to Immunome's net margin of -1,875.21%. Vor Biopharma's return on equity of 0.00% beat Immunome's return on equity.

Company Net Margins Return on Equity Return on Assets
Immunome-1,875.21% -71.65% -60.36%
Vor Biopharma N/A N/A N/A

44.6% of Immunome shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 8.6% of Immunome shares are owned by company insiders. Comparatively, 2.9% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Vor Biopharma beats Immunome on 8 of the 13 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VOR vs. The Competition

MetricVor BiopharmaBiological Products, Except Diagnostic Substances IndustryMedical SectorNYSE Exchange
Market Cap$372.71M$315.88M$5.44B$20.42B
Dividend YieldN/AN/A5.22%3.72%
P/E Ratio-1.81N/A27.2527.79
Price / SalesN/AN/A426.5038.15
Price / CashN/AN/A26.2118.22
Price / BookN/AN/A7.924.58
Net IncomeN/AN/A$3.17B$982.91M
7 Day Performance84.11%46.73%4.48%1.63%
1 Month Performance1,232.71%1,289.63%2.80%4.23%
1 Year Performance228.48%242.51%35.04%14.20%

Vor Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VOR
Vor Biopharma
3.9713 of 5 stars
$2.98
+56.2%
$5.63
+88.7%
+107.6%$372.71MN/A-1.81140Gap Up
High Trading Volume
IMNM
Immunome
2.4359 of 5 stars
$9.30
+6.0%
$23.33
+150.9%
-27.6%$809.19M$9.04M-2.9240High Trading Volume
SNDX
Syndax Pharmaceuticals
3.1309 of 5 stars
$9.36
+3.5%
$35.80
+282.5%
-55.7%$805.43M$23.68M-2.42110
CMRX
Chimerix
0.6276 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212K-9.0990
CDMO
Avid Bioservices
0.6885 of 5 stars
$12.50
+0.1%
$12.25
-2.0%
+68.4%$799.18M$139.91M-5.23320High Trading Volume
AVXL
Anavex Life Sciences
3.5773 of 5 stars
$9.22
-2.7%
$44.00
+377.2%
+155.8%$787.13MN/A-16.7640Positive News
SION
Sionna Therapeutics
N/A$17.35
+9.5%
$38.50
+121.9%
N/A$765.48MN/A0.0035Gap Up
QURE
uniQure
2.1025 of 5 stars
$13.94
+0.6%
$37.82
+171.3%
+277.2%$763.63M$27.12M-3.18500
AVBP
ArriVent BioPharma
1.7434 of 5 stars
$21.77
-5.0%
$40.00
+83.7%
+11.6%$744.75MN/A-5.7740
CRON
Cronos Group
1.9914 of 5 stars
$1.91
+0.5%
N/A-8.5%$736.65M$117.61M14.69450
XERS
Xeris Biopharma
3.6178 of 5 stars
$4.67
-0.6%
$6.25
+33.8%
+125.4%$730.30M$203.07M-15.57290Positive News

Related Companies and Tools


This page (NYSE:VOR) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners